Psych Capital Plc Logo

Psych Capital Plc

PSY | IL

Overview

Corporate Details

ISIN(s):
GB00BL6CJQ54
LEI:
213800WXCQ1C6GPLHH68
Country:
United Kingdom
Address:
17 HANOVER SQUARE, W1S 1BN LONDON
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Shortwave Life Sciences Plc, formerly Psych Capital Plc, is a life sciences company focused on developing innovative treatments for mental health conditions. The company's lead clinical program is centered on a psilocybin-based therapy for anorexia nervosa, a life-threatening condition with no currently FDA-approved medication. Leveraging an IP-driven approach rooted in the Israeli innovation ecosystem, Shortwave utilizes a capital-efficient economic model that combines in-house capabilities with strategic partnerships for drug discovery and development. The firm is dedicated to identifying, operating, and creating value from early-stage, breakthrough initiatives to address unmet patient needs in eating disorders and mental healthcare.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Psych Capital Plc. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-19 13:50
Major Shareholding Notification
Holding(s) in Company
English 56.0 KB
2025-08-04 12:00
Board/Management Information
Clarification on Strategic Advisor Appointment
English 6.0 KB
2025-07-29 08:00
Share Issue/Capital Change
£250k Fundraising, New Directors & Review
English 27.3 KB
2025-06-24 14:10
Major Shareholding Notification
AQSE Only - Holding(s) in Company
English 56.2 KB
2025-06-16 11:21
Major Shareholding Notification
Holding(s) in Company
English 56.2 KB
2025-01-31 17:52
Earnings Release
Interim Results to 31 October 2024
English 115.6 KB
2024-12-23 13:00
Share Issue/Capital Change
Pre-Crowdfunding re Groundbreaking Treatment
English 9.5 KB
2024-11-29 16:16
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 7.2 KB
2024-11-27 15:12
Board/Management Information
Director Appointment and SPA Update
English 26.7 KB
2024-10-31 18:39
Annual Report
YEAR ENDED 30 APRIL 2024 AND DIRECTOR RESIGNATION
English 176.8 KB
2024-09-19 08:00
Regulatory News Service
Positive Pre-Clinical Result Drive to Human Trials
English 10.7 KB
2024-07-31 13:05
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 7.2 KB
2024-07-17 18:20
Major Shareholding Notification
TR1: Notification of Major Holdings
English 75.8 KB
2024-07-08 08:00
Share Issue/Capital Change
Company’s Patent Claims Confirmed
English 31.5 KB
2024-07-03 16:49
Major Shareholding Notification
Holding(s) in Company
English 75.8 KB

Automate Your Workflow. Get a real-time feed of all Psych Capital Plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Psych Capital Plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
PILA PHARMA AB Logo
Clinical-stage biopharma developing a first-in-class oral drug for diabetes and obesity.
Sweden PILA
Plantarc Bio Ltd. Logo
Agritech firm using gene discovery & editing to improve crop yield, resilience, and pest control.
Israel PLNT
POLAREAN IMAGING PLC Logo United States of America POLX
Poltreg S.A. Logo
Develops T-regulatory cell (Treg) therapies for autoimmune diseases like diabetes and MS.
Poland PTG
POOLBEG PHARMA PLC Logo
AI-led biopharma developing drugs for high-need diseases like CRS and metabolic disorders.
United Kingdom POLB
Poxel Logo
Biopharma developing treatments for metabolic diseases like NASH, with a marketed drug for diabetes.
France POXEL
PROTEOME SCIENCES PLC Logo
CRO providing proteomics services & TMT® tags to biopharma for drug discovery & biomarkers.
United Kingdom PRM
PROVEXIS PLC Logo
Develops & licenses Fruitflow®, a patented ingredient for heart health in food & supplements.
United Kingdom PXS
Pure Biologics S.A. Logo
Develops novel antibody and aptamer drugs for immuno-oncology and autoimmunity.
Poland PUR
Puretech Health PLC Logo United States of America PRTC